HARVARD BIOSCIENCE INC (HBIO) Stock Fundamental Analysis
USA - NASDAQ:HBIO - US4169061052 - Common Stock
0.4849 USD
+0.05 (+10.33%)
0.4651 USD
-0.02 (-4.08%)
We assign a fundamental rating of 3 out of 10 to HBIO. HBIO was compared to 55 industry peers in the Life Sciences Tools & Services industry. HBIO may be in some trouble as it scores bad on both profitability and health. HBIO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
HBIO had positive earnings in the past year.
HBIO had a positive operating cash flow in the past year.
In the past 5 years HBIO always reported negative net income.
Each year in the past 5 years HBIO had a positive operating cash flow.
1.2 Ratios
The Return On Assets of HBIO (-71.67%) is worse than 90.91% of its industry peers.
HBIO has a worse Return On Equity (-364.88%) than 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HBIO has a better Gross Margin (56.89%) than 72.73% of its industry peers.
HBIO's Gross Margin has been stable in the last couple of years.
HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HBIO has more shares outstanding
The number of shares outstanding for HBIO has been increased compared to 5 years ago.
The debt/assets ratio for HBIO is higher compared to a year ago.
2.2 Solvency
HBIO has an Altman-Z score of -2.70. This is a bad value and indicates that HBIO is not financially healthy and even has some risk of bankruptcy.
HBIO's Altman-Z score of -2.70 is on the low side compared to the rest of the industry. HBIO is outperformed by 83.64% of its industry peers.
There is no outstanding debt for HBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Altman-Z | -2.7 |
ROIC/WACCN/A
WACC10.17%
2.3 Liquidity
HBIO has a Current Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.81, HBIO is not doing good in the industry: 94.55% of the companies in the same industry are doing better.
A Quick Ratio of 0.41 indicates that HBIO may have some problems paying its short term obligations.
HBIO's Quick ratio of 0.41 is on the low side compared to the rest of the industry. HBIO is outperformed by 98.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
The earnings per share for HBIO have decreased strongly by -71.43% in the last year.
The earnings per share for HBIO have been decreasing by -19.73% on average. This is quite bad
The Revenue for HBIO has decreased by -12.24% in the past year. This is quite bad
Measured over the past years, HBIO shows a decrease in Revenue. The Revenue has been decreasing by -4.12% on average per year.
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
3.2 Future
The Earnings Per Share is expected to grow by 27.08% on average over the next years. This is a very strong growth
Based on estimates for the next years, HBIO will show a decrease in Revenue. The Revenue will decrease by -1.21% on average per year.
EPS Next Y-57.5%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 24.25, the valuation of HBIO can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 81.82% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.20, HBIO is valued at the same level.
Based on the Price/Forward Earnings ratio of 5.00, the valuation of HBIO can be described as very cheap.
100.00% of the companies in the same industry are more expensive than HBIO, based on the Price/Forward Earnings ratio.
HBIO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.71.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.25 | ||
| Fwd PE | 5 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 81.82% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.23 | ||
| EV/EBITDA | 15.84 |
4.3 Compensation for Growth
HBIO's earnings are expected to grow with 27.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.08%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for HBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.4849
+0.05 (+10.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners72.67%
Inst Owner Change-26.64%
Ins Owners1.48%
Ins Owner Change10.72%
Market Cap21.59M
Analysts80
Price Target2.04 (320.71%)
Short Float %1.9%
Short Ratio1.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)1.96%
Max EPS beat(2)75.49%
EPS beat(4)3
Avg EPS beat(4)-19.61%
Min EPS beat(4)-173.52%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-36.43%
EPS beat(12)5
Avg EPS beat(12)-34.08%
EPS beat(16)5
Avg EPS beat(16)-29.83%
Revenue beat(2)1
Avg Revenue beat(2)4.73%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)11.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.43%
Min Revenue beat(4)-14.86%
Max Revenue beat(4)11.18%
Revenue beat(8)1
Avg Revenue beat(8)-5.4%
Revenue beat(12)2
Avg Revenue beat(12)-5.25%
Revenue beat(16)3
Avg Revenue beat(16)-4.28%
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-50%
EPS NY rev (3m)-44.44%
Revenue NQ rev (1m)-1.23%
Revenue NQ rev (3m)-8.05%
Revenue NY rev (1m)-1.89%
Revenue NY rev (3m)-1.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.25 | ||
| Fwd PE | 5 | ||
| P/S | 0.24 | ||
| P/FCF | 5.23 | ||
| P/OCF | 3.26 | ||
| P/B | 1.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.84 |
EPS(TTM)0.02
EY4.12%
EPS(NY)0.1
Fwd EY19.98%
FCF(TTM)0.09
FCFY19.13%
OCF(TTM)0.15
OCFY30.68%
SpS1.99
BVpS0.35
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.89% | ||
| FCFM | 4.65% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 8.44 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.42% | ||
| Cap/Sales | 2.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 223.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.7 |
F-Score4
WACC10.17%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.43%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%23.48%
EPS Next Y-57.5%
EPS Next 2Y27.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.24%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-11.46%
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4733.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.77%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%